Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday. The firm presently has a $1.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price points to a potential upside of 2.73% from the company’s current price.

According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “

Several other brokerages also recently issued reports on APTO. Canaccord Genuity restated a “buy” rating and set a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, May 12th. HC Wainwright initiated coverage on shares of Aptose Biosciences in a research report on Thursday, June 8th. They set a “hold” rating for the company. ValuEngine upgraded shares of Aptose Biosciences from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 12th. Finally, Rodman & Renshaw began coverage on shares of Aptose Biosciences in a research report on Thursday, June 8th. They set a “neutral” rating for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.13.

Aptose Biosciences (APTO) traded up 0.6966% during midday trading on Monday, hitting $1.4601. The stock had a trading volume of 171,255 shares. The company’s 50 day moving average is $1.43 and its 200 day moving average is $1.17. Aptose Biosciences has a 1-year low of $0.78 and a 1-year high of $3.20. The company’s market cap is $31.76 million.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.07. On average, equities analysts anticipate that Aptose Biosciences will post ($1.04) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Aptose Biosciences, Inc. (NASDAQ:APTO) Lifted to “Buy” at Zacks Investment Research” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/08/14/aptose-biosciences-inc-nasdaqapto-lifted-to-buy-at-zacks-investment-research.html.

Aptose Biosciences Company Profile

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.